If You Invested in APOLLOMICS INC (APLM)

Apollomics Inc. (Nasdaq: APLM) is a clinical-stage biopharmaceutical and biotechnology company focused on the discovery and development of oncology therapies. The company describes itself as advancing oncology drug candidates that have the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways involved in cancer. Apollomics develops multiple oncology drug candidates aimed at difficult-to-treat and treatment-resistant cancers, including lung cancer, brain cancer and other solid tumors.

Apollomics is a late-stage clinical biopharmaceutical company with a pipeline that, according to its disclosures, includes nine product candidates across 11 programs, with six in clinical development. Its strategic approach combines targeted therapies, immuno-oncology and novel mechanisms of action designed to address resistance and improve clinical outcomes in oncology. The company’s securities trade on The Nasdaq Stock Market under the symbol APLM.

Core programs and oncology focus

Apollomics’ lead program is vebreltinib (APL-101), which the company describes as a potent, selective and orally bioavailable c-Met inhibitor. Vebreltinib is being developed for the treatment of non-small cell lung cancer (NSCLC) and other advanced tumors with c-Met alterations or MET dysregulation. The company reports that vebreltinib is currently in a Phase 2 multicohort global clinical trial (often referred to as the SPARTA trial) in the United States and other countries, and that clinical trials have involved more than 280 patients.

Apollomics highlights vebreltinib as a core investment and a central focus of its development strategy. The company states that it is conducting a global, multi-country, multi-center Phase 2 trial designed to evaluate vebreltinib across multiple tumor types with MET dysregulation, including NSCLC with MET amplification, NSCLC with MET exon 14 skipping, and non-central nervous system solid tumors with MET fusions. The company also notes that its partner in China, Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd, has obtained conditional approval from the National Medical Products Administration (NMPA) of China for vebreltinib for multiple indications, and that Apollomics intends to leverage Chinese approvals to pursue regulatory submissions in other regions.

Pipeline breadth and other programs

Beyond vebreltinib, Apollomics has disclosed additional oncology programs. The company previously described uproleselan (APL-106), a specific E-selectin antagonist, as a program that could be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Apollomics conducted a Phase 3 bridging trial of uproleselan in China in patients with relapsed or refractory acute myeloid leukemia. The company reported that this trial did not demonstrate favorable benefit for uproleselan compared to chemotherapy alone and that it is wrapping up this program, with expectations that future expenses related to uproleselan will be limited.

Apollomics has also disclosed programs such as APL-122 and APL-102. APL-122 was described as an oral, irreversible pan-ErbB inhibitor targeting EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) kinases, designed with blood-brain barrier penetration capabilities to treat ErbB-positive cancers, particularly in patients with central nervous system metastases. The company licensed rights to APL-122 from Edison Oncology Holding Corporation and reported dose escalation work in a Phase 1 trial. In December 2025, Apollomics disclosed that it had terminated its development and license agreement with Edison regarding APL-122 based on alleged non-performance by Edison and stated that it does not expect this termination to have a material adverse effect on its overall financial condition or results of operations.

APL-102 is described by Apollomics as an oral, small molecule multi-target kinase inhibitor (MTKi) targeting the VEGFR and MAPK pathways via B-RAF and C-RAF, and colony stimulating factor 1 receptor. The company reports that a Phase 1 clinical trial of APL-102 in China has been closed and that it expects to provide topline results.

Strategic collaborations and geographic reach

Apollomics has entered into collaboration and licensing arrangements to expand the development and potential commercialization of its oncology assets. The company announced an agreement with LaunXP International Co., Ltd., an affiliate of LaunXP Biomedical Co., Ltd., granting LaunXP exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of NSCLC. Under this agreement, Apollomics is to receive upfront payments, may be eligible for regulatory and pre-commercial milestone payments, and may receive royalties on net product sales. The company later reported receiving a payment from LaunXP and stated that the agreement remains in full force and effect, with both parties continuing to perform their obligations.

Apollomics also references relationships with clinical research organizations and licensing partners, including Sofpromed Investigación Clínica, S.L. for SPARTA trials, Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd in China, and LaunXP Biomedical Co., Ltd. in Taiwan. The company has indicated that it intends to use Chinese approvals for APL-101 (vebreltinib) in MET-amplified NSCLC and glioblastoma to support regulatory submissions in regions such as Southeast Asia and the Middle East, as well as other potential emerging markets outside of China.

Corporate developments and listing status

Apollomics is based in Foster City, California, and reports that it operates as a foreign private issuer under the Securities Exchange Act of 1934, filing reports on Form 20-F and Form 6-K. The company completed a merger with Maxpro Capital Acquisition Corporation in 2023, which is referenced in connection with litigation involving minority investors and preferred share redemptions.

The company’s Class A ordinary shares trade on the Nasdaq Capital Market under the symbol APLM. Apollomics has disclosed interactions with Nasdaq’s Listing Qualifications Staff, including receiving a delisting determination letter based on Nasdaq’s view that the company was a “public shell,” appealing that determination, and later reporting that Nasdaq determined the company is in compliance with continued listing requirements. The company also announced that it regained compliance with Nasdaq’s minimum bid price requirement and implemented a 1-for-100 reverse share split of its Class A ordinary shares, with the shares continuing to trade under the symbol APLM.

Operational continuity and business plan

In 2025, Apollomics reported that, due to financial concerns, its former board and management had previously stated an expectation to discontinue clinical trial activities related to APL-101 (vebreltinib) and to seek shareholder approval to wind up the company’s business. Subsequent disclosures describe a change in direction following new funding and leadership. The company reported receiving PIPE investments, appointing a new board of directors and new management, and reversing prior wind-up plans. Apollomics states that it is continuing pre-existing operations, maintaining its clinical trials, and advancing the global development and commercialization of its intellectual property assets, particularly APL-101 (vebreltinib).

Apollomics has described a business plan for a 12-month period aimed at ensuring continued operations and strengthening its clinical development programs. It has also provided information on its workforce, including a small number of full-time employees, and its intention to adjust headcount between regions such as China, the United States and Taiwan to support its operations and clinical activities.

Financial reporting and governance

As a public company, Apollomics publishes financial statements and other disclosures, including interim and annual results that detail its research and development expenses, administrative expenses, impairment of intangible assets and net losses. The company has reported that it is a clinical-stage entity with no indication of commercial product revenue in earlier periods, and later reported revenue and other income in interim financial statements. It has disclosed changes in its audit firm, noting the dismissal of its previous independent registered public accounting firm and the appointment of a new auditor, and has described remediation of a previously identified material weakness in internal control over financial reporting.

Apollomics has also reported legal and regulatory matters, including the Cayman Litigation involving minority investors related to its merger with Maxpro Capital Acquisition Corporation. The company announced a settlement agreement to fully resolve and conclude all matters related to this litigation, including agreed cash payments and associated legal expenses, subject to court approval.

Position within the biotechnology sector

Within the biotechnology and professional, scientific and technical services sector, Apollomics positions itself as a company focused on oncology drug development, with an emphasis on targeted therapies that address specific molecular pathways such as c-Met and ErbB family receptors, as well as immuno-oncology approaches. Its disclosures emphasize a focus on difficult-to-treat and treatment-resistant cancers, multi-regional clinical development, and collaborations with partners and clinical research organizations. Investors following APLM stock can use these structural and strategic details to understand the company’s stated objectives, areas of therapeutic focus and the nature of its clinical-stage risk profile.